Niraparib + Dostarlimab + RT in Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

January 19, 2022

Study Completion Date

February 25, 2022

Conditions
Pancreatic CancerMetastatic Pancreatic Cancer
Interventions
DRUG

Niraparib

Niraparib oral, once a day, predetermined dose.Dosing will commence on cycle 1 day 1 and will continue until the participant is taken off treatment

DRUG

Dostarlimab

Dostarlimab by intravenous infusion once every cycle for as long as they remain on the study

RADIATION

Radiation

Radiation therapy on every other week day of cycle 2 only. Radiation will begin on Cycle 2 Day 1

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

Tesaro, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04409002 - Niraparib + Dostarlimab + RT in Pancreatic Cancer | Biotech Hunter | Biotech Hunter